LEVOSIMENDAN REDUCES MORTALITY IN PATIENTS WITH REDUCED EJECTION FRACTION UNDERGOING CARDIAC SURGERY: A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS  by Harrison, Robert et al.
Heart Failure
E959
JACC March 27, 2012
Volume 59, Issue 13
LEVOSIMENDAN REDUCES MORTALITY IN PATIENTS WITH REDUCED EJECTION FRACTION UNDERGOING 
CARDIAC SURGERY: A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS
ACC Moderated Poster Contributions
McCormick Place South, Hall A
Monday, March 26, 2012, 9:30 a.m.-10:30 a.m.
Session Title: Pharmacological Therapy: Matching Patient and Drug for Optimal Outcome
Abstract Category: 14. Heart Failure: Clinical
Presentation Number: 1229-604
Authors: Robert Harrison, Victor Hasselblad, Ricardo Levin, Rajendra Mehta, Robert Harrington, John Alexander, Duke Clinical Research Institute, 
Durham, NC, USA
Background:  Left ventricular systolic dysfunction is associated with increased mortality in patients undergoing cardiac surgery. Levosimendan has 
been shown in several small clinical trials to improve outcomes in cardiac surgery. We performed a meta-analysis of trials investigating levosimendan 
in patients with reduced ejection fraction (EF) undergoing cardiac surgery.
Methods:  PubMed, Embase, and conference proceedings were searched for clinical trials of perioperative levosimendan in patients undergoing 
cardiac surgery. The company marketing levosimendan (Orion Pharma) was also contacted regarding unpublished data. Randomized clinical trials of 
patients with a mean EF ≤40% were included in the analysis. Our primary endpoint was study reported mortality out to 30 days.
Results:  480 abstracts were reviewed. Nine studies, totaling 796 randomized patients, were included in the analysis. Levosimendan was 
administered preoperatively in one study, intraoperatively in five studies, and postoperatively in three studies. Levosimendan was associated with 
reduced morbidity and mortality (see table) as well as a decrease in postoperative atrial fibrillation (odds ratio 0.35; 95% CI 0.27-0.58).
Conclusion:  Levosimendan use was associated with improved morbidity and mortality in patients with reduced ejection fraction undergoing 
cardiac surgery. These data support the need for an adequately powered randomized clinical trial of levosimendan in this patient population. 
Outcome Trials Control Levosimendan Difference in rates (95% CI) P-Value
Mortality 9 12.1% 4.4% 8.7% (3.8%-14.3%) <0.001
New Dialysis 4 6.6% 1.7% 4.7% (1.5%-8.2%) 0.044
Myocardial Injury 5 8.3% 1.6% 6.5% (3.3%-10.1%) 0.046
